|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US6054312A
(en)
|
1997-08-29 |
2000-04-25 |
Selective Genetics, Inc. |
Receptor-mediated gene delivery using bacteriophage vectors
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
PT1391464E
(pt)
|
2001-04-27 |
2007-11-15 |
Kirin Pharma Kk |
Anticorpo monoclonal anti-cd40
|
|
ES2350687T3
(es)
|
2002-07-03 |
2011-01-26 |
Ono Pharmaceutical Co., Ltd. |
Composiciones de inmunopotenciación.
|
|
US7186699B2
(en)
|
2003-06-03 |
2007-03-06 |
Cell Genesys, Inc. |
Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
BRPI0417266B8
(pt)
|
2003-12-25 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
anticorpo monoclonal, seu uso e composição farmacêutica
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
US7588772B2
(en)
*
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
MX2008013508A
(es)
|
2006-04-21 |
2008-10-31 |
Novartis Ag |
Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
|
|
WO2009012176A2
(en)
|
2007-07-14 |
2009-01-22 |
The University Of Iowa Research Foundation |
Methods and compositions for treating brain diseases
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
JP2012525146A
(ja)
|
2009-04-28 |
2012-10-22 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
細胞透過のための過剰に荷電されたタンパク質
|
|
BR112012024713B1
(pt)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
|
EP2826860B1
(en)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
CNS targeting AAV vectors and methods of use thereof
|
|
US8628966B2
(en)
|
2010-04-30 |
2014-01-14 |
City Of Hope |
CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
|
|
US8927514B2
(en)
|
2010-04-30 |
2015-01-06 |
City Of Hope |
Recombinant adeno-associated vectors for targeted treatment
|
|
JP5458188B2
(ja)
|
2011-02-17 |
2014-04-02 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
HRP20171334T1
(hr)
|
2011-04-22 |
2017-11-17 |
The Regents Of The University Of California |
Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
|
|
CN113461819B
(zh)
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
HRP20201595T1
(hr)
|
2011-11-28 |
2020-12-11 |
Merck Patent Gmbh |
Anti-pd-l1 protutijela i njihova uporaba
|
|
US9636370B2
(en)
|
2012-09-28 |
2017-05-02 |
The University Of North Carolina At Chapel Hill |
AAV vectors targeted to oligodendrocytes
|
|
BR112015008673A2
(pt)
|
2012-10-17 |
2017-09-26 |
Fond Telethon |
composto, composição farmacêutica e método
|
|
AU2013337903B2
(en)
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
TR201905612T4
(tr)
|
2012-12-05 |
2019-05-21 |
Univ Heidelberg Ruprecht Karls |
Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları.
|
|
SG11201509742QA
(en)
|
2013-06-03 |
2015-12-30 |
Novartis Ag |
Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
|
|
US9585971B2
(en)
|
2013-09-13 |
2017-03-07 |
California Institute Of Technology |
Recombinant AAV capsid protein
|
|
WO2015127094A1
(en)
|
2014-02-19 |
2015-08-27 |
University Of Florida Research Foundation, Inc. |
Delivery of nrf2 as therapy for protection against reactive oxygen species
|
|
WO2015138628A1
(en)
|
2014-03-11 |
2015-09-17 |
University Of Florida Research Foundation, Inc. |
Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
ES2916923T3
(es)
|
2014-07-11 |
2022-07-06 |
Ventana Med Syst Inc |
Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
US10501733B2
(en)
|
2015-02-27 |
2019-12-10 |
University Of Washington |
Polypeptide assemblies and methods for the production thereof
|
|
US20180133327A1
(en)
|
2015-03-16 |
2018-05-17 |
Amal Therapeutics Sa |
Cell Penetrating Peptides and Complexes Comprising the Same
|
|
CA2988388C
(en)
|
2015-04-23 |
2022-11-22 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CN104965364B
(zh)
|
2015-07-14 |
2018-03-30 |
武汉华星光电技术有限公司 |
阵列基板及驱动阵列基板的方法
|
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
|
CA2947904A1
(en)
|
2015-11-12 |
2017-05-12 |
Pfizer Inc. |
Tissue-specific genome engineering using crispr-cas9
|
|
KR102423442B1
(ko)
|
2015-12-11 |
2022-07-20 |
캘리포니아 인스티튜트 오브 테크놀로지 |
아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드
|
|
CN106939047B
(zh)
|
2016-01-04 |
2021-08-31 |
江苏怀瑜药业有限公司 |
一种pd-l1抗体及其制备方法
|
|
WO2017136536A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
|
BR112019016769A2
(pt)
|
2017-02-15 |
2020-05-26 |
The University Of North Carolina At Chapel Hill |
Métodos e composições para transferência genética através da vasculatura
|
|
WO2019012176A1
(en)
|
2017-07-11 |
2019-01-17 |
Outotec (Finland) Oy |
WATERING APPARATUS
|
|
JP7221275B2
(ja)
|
2017-08-03 |
2023-02-13 |
ボイジャー セラピューティクス インコーポレイテッド |
Ａａｖを送達するための組成物および方法
|
|
US11905533B2
(en)
|
2017-12-19 |
2024-02-20 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for delivery of viral vectors across the blood-brain barrier
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
US20210207167A1
(en)
|
2018-05-16 |
2021-07-08 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
CA3103372A1
(en)
|
2018-06-27 |
2020-01-02 |
Precigen, Inc. |
In vivo controlled combination therapy for treatment of cancer
|
|
CN112703198B
(zh)
|
2018-07-11 |
2025-05-30 |
布里格姆妇女医院 |
用于跨血脑屏障递送试剂的方法和组合物
|
|
US20210277418A1
(en)
|
2018-08-03 |
2021-09-09 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
WO2020068990A1
(en)
|
2018-09-26 |
2020-04-02 |
California Institute Of Technology |
Adeno-associated virus compositions for targeted gene therapy
|
|
EP3861010A1
(en)
|
2018-10-02 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
EP3917945A4
(en)
|
2019-01-30 |
2023-02-08 |
The Broad Institute Inc. |
ADVANCED ADENO-ASSOCIATED VIRUS (AAVS) TARGETED DELIVERY SYSTEMS
|
|
AU2020271108A1
(en)
|
2019-04-11 |
2021-11-11 |
California Institute Of Technology |
Virus compositions with enhanced specificity in the brain
|
|
WO2020223279A1
(en)
|
2019-04-29 |
2020-11-05 |
Voyager Therapeutics, Inc. |
VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
|
|
WO2021025995A1
(en)
|
2019-08-02 |
2021-02-11 |
Voyager Therapeutics, Inc. |
Aav variants with enhanced tropism
|
|
US20240285804A1
(en)
|
2021-06-21 |
2024-08-29 |
The Brigham And Women's Hospital, Inc. |
Adeno-associated viral (aav) vectors for tissue-targeted expression of therapeutic genes
|